^
Association details:
| Biomarker: | HR negative |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug Class: | CDK19 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2647 / 16 - RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo
Published date:
03/09/2022
Excerpt:
These studies revealed that TNBC and ER-/PR-/HER2+ cells were highly sensitive to RVU120 and also to two other non-related CDK8/19 inhibitors, indicating a class effect.
